These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24205185)

  • 1. A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants.
    Afolabi MO; Ndure J; Drammeh A; Darboe F; Mehedi SR; Rowland-Jones SL; Borthwick N; Black A; Ambler G; John-Stewart GC; Reilly M; Hanke T; Flanagan KL
    PLoS One; 2013; 8(10):e78289. PubMed ID: 24205185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PedVacc 002: a phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi.
    Njuguna IN; Ambler G; Reilly M; Ondondo B; Kanyugo M; Lohman-Payne B; Gichuhi C; Borthwick N; Black A; Mehedi SR; Sun J; Maleche-Obimbo E; Chohan B; John-Stewart GC; Jaoko W; Hanke T
    Vaccine; 2014 Oct; 32(44):5801-8. PubMed ID: 25173484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
    Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
    J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
    Cebere I; Dorrell L; McShane H; Simmons A; McCormack S; Schmidt C; Smith C; Brooks M; Roberts JE; Darwin SC; Fast PE; Conlon C; Rowland-Jones S; McMichael AJ; Hanke T
    Vaccine; 2006 Jan; 24(4):417-25. PubMed ID: 16176847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
    Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
    Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.
    Sandström E; Nilsson C; Hejdeman B; Bråve A; Bratt G; Robb M; Cox J; Vancott T; Marovich M; Stout R; Aboud S; Bakari M; Pallangyo K; Ljungberg K; Moss B; Earl P; Michael N; Birx D; Mhalu F; Wahren B; Biberfeld G;
    J Infect Dis; 2008 Nov; 198(10):1482-90. PubMed ID: 18808335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
    Rosario M; Fulkerson J; Soneji S; Parker J; Im EJ; Borthwick N; Bridgeman A; Bourne C; Joseph J; Sadoff JC; Hanke T
    J Virol; 2010 Aug; 84(15):7815-21. PubMed ID: 20484495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
    Viegas EO; Kroidl A; Munseri PJ; Missanga M; Nilsson C; Tembe N; Bauer A; Joachim A; Joseph S; Mann P; Geldmacher C; Fleck S; Stöhr W; Scarlatti G; Aboud S; Bakari M; Maboko L; Hoelscher M; Wahren B; Robb ML; Weber J; McCormack S; Biberfeld G; Jani IV; Sandström E; Lyamuya E;
    PLoS One; 2018; 13(11):e0206838. PubMed ID: 30496299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
    Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
    Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
    Currier JR; Ngauy V; de Souza MS; Ratto-Kim S; Cox JH; Polonis VR; Earl P; Moss B; Peel S; Slike B; Sriplienchan S; Thongcharoen P; Paris RM; Robb ML; Kim J; Michael NL; Marovich MA
    PLoS One; 2010 Nov; 5(11):e13983. PubMed ID: 21085591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
    Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J
    PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
    Mwau M; Cebere I; Sutton J; Chikoti P; Winstone N; Wee EG; Beattie T; Chen YH; Dorrell L; McShane H; Schmidt C; Brooks M; Patel S; Roberts J; Conlon C; Rowland-Jones SL; Bwayo JJ; McMichael AJ; Hanke T
    J Gen Virol; 2004 Apr; 85(Pt 4):911-919. PubMed ID: 15039533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.
    Hopkins R; Bridgeman A; Bourne C; Mbewe-Mvula A; Sadoff JC; Both GW; Joseph J; Fulkerson J; Hanke T
    Eur J Immunol; 2011 Dec; 41(12):3542-52. PubMed ID: 21932450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
    Hanke T; McMichael AJ; Dorrell L
    J Gen Virol; 2007 Jan; 88(Pt 1):1-12. PubMed ID: 17170430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.
    Hanke T; Barnfield C; Wee EG; Ågren L; Samuel RV; Larke N; Liljeström P
    J Gen Virol; 2003 Feb; 84(Pt 2):361-368. PubMed ID: 12560568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a DNA-MVA/HIVA vaccine for Kenya.
    Hanke T; McMichael AJ; Mwau M; Wee EG; Ceberej I; Patel S; Sutton J; Tomlinson M; Samuel RV
    Vaccine; 2002 May; 20(15):1995-8. PubMed ID: 11983261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques.
    Phillips B; Fouda GG; Eudailey J; Pollara J; Curtis AD; Kunz E; Dennis M; Shen X; Bay C; Hudgens M; Pickup D; Alam SM; Ardeshir A; Kozlowski PA; Van Rompay KKA; Ferrari G; Moody MA; Permar S; De Paris K
    Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28814388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.
    Hayton EJ; Rose A; Ibrahimsa U; Del Sorbo M; Capone S; Crook A; Black AP; Dorrell L; Hanke T
    PLoS One; 2014; 9(7):e101591. PubMed ID: 25007091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.